CanSino Biologics Inc. (6185.HK) HKSE
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
CanSino Biologics Inc.
Address
401-420, Biomedical Park
Tianjin, 300457
Hong Kong
Phone
400 922 2099
Website
Sector
Healthcare
Industry
Biotechnology
Employees
1134
First IPO Date
November 18, 2010
Key Executives
| Name | Title | Pay | Year Born |
| Xuefeng Yu | Co-Founder, Executive Chairman, Chief Executive Officer & GM | 4.41M | 1964 |
| Shou-Bai Chao | Chief Operating Officer, Deputy GM & Executive Director | 2.94M | 1963 |
| Jing Wang | Chief Commercial Officer, Deputy GM & Executive Director | 3.87M | 1981 |
| Dongxu Qiu | Co-Founder, Executive Vice President & Deputy GM | 4.11M | 1960 |
| Tao Zhu | Co-Founder, Deputy GM & Chief Scientific Officer | 4.86M | 1973 |
| Chunlin Xin | Senior Director of New Technology Department | 0 | N/A |
| Jin Cui | Board Secretary | 0 | 1987 |
| Ming King Chiu FCIS | Joint Company Secretary | 0 | 1977 |
| Yonghui Wu | Vice President of Marketing | 0 | N/A |
| Bei Bei Gao | Accounting Supervisor | 0 | N/A |
| Ming Liu | Acting Head of Finance | 0 | N/A |
Description
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People’s Republic of China.
